Kotak upgrades Dabur to Add after 25% correction, despite lower ₹430 fair value
Kotak Institutional Equities upgraded Dabur India from Reduce to Add, citing more reasonable valuations and potential execution gains under new India CEO Herjit Bhalla. The brokerage expects 9–10% revenue and EPS growth in FY2026–27, while flagging weakness in health supplement beverages.
What happened
Kotak upgraded Dabur India to Add after a roughly 25% four-month stock correction, citing reasonable valuations and expected execution improvement under new
Key facts
- Kotak upgraded Dabur to Add from Reduce
- Fair value revised to Rs430 per share from Rs465
- Valuation multiple revised to 33x September 2028E P/E from 35x
- Stock corrected about 25% over four months
- FY2026-27 revenue and EPS growth estimated at 9-10%
- BSE closing price: Rs384 per share
- Market capitalisation: Rs67,942.55 crore
- 2026 YTD share-price decline: 23.4%
- One-year share-price decline: 28.44%
- ROE: 21.26%
Why this matters
The signal highlights an opportunity for Dabur to strengthen or reshape its health supplement beverage portfolio as leadership changes seek to unlock execution-led growth.
What to watch
- India volume growth versus the 9-10% FY2026-27 revenue and EPS growth expectation.
- Performance of health supplement beverages, including market-share trends, innovation success and promotional intensity.
- Commentary from Herjit Bhalla on distribution expansion, rural demand, portfolio changes and execution priorities.
- Gross-margin and EBITDA-margin progression amid input-cost movements and higher brand investment.
- Rural versus urban consumption trends, monsoon conditions and seasonal healthcare demand.
- Any further target-price changes or upgrades from other brokerages following earnings delivery.
- Management is likely to emphasise portfolio rationalisation, distribution productivity and sharper execution in India under Herjit Bhalla.
- Investor attention will shift from the upgrade itself to evidence of volume-growth acceleration in the next two to three quarterly results.
- Dabur may increase promotional, innovation and channel investments in health beverages and adjacent wellness categories, potentially creating near-term margin trade-offs.
- Peer comparisons with other defensive FMCG names may improve if Dabur delivers stable margins at a comparatively undemanding valuation.